Abstract:Heparins have been invaluable therapeutic anticoagulant polysaccharides for over a century, whether used as unfractionated heparin or as low molecular weight heparin (LMWH) derivatives. However, heparin production by extraction from animal tissues presents multiple challenges, including the risk of adulteration, contamination, prion and viral impurities, limited supply, insecure supply chain, and significant batch-to-batch variability. The use of animal-derived heparin also raises ethical and religious concerns, as well as carries the risk of transmitting zoonotic diseases. Chemoenzymatic synthesis of animal-free heparin products would offer several advantages, including reliable and scalable production processes, improved purity and consistency, and the ability to produce heparin polysaccharides with molecular weight, structural, and functional properties equivalent to those of the United States Pharmacopeia (USP) heparin, currently only sourced from porcine intestinal mucosa. We report a scalable process for the production of bioengineered heparin that is biologically and compositionally similar to USP heparin. This process relies on enzymes from the heparin biosynthetic pathway, immobilized on an inert support and requires a tailored N-sulfoheparosan with N-sulfo levels similar to those of porcine heparins. We also report the conversion of our bioengineered heparin into a LMWH that is biologically and compositionally similar to USP enoxaparin. Ultimately, we demonstrate major advances to a process to provide a potential clinical and sustainable alternative to porcine-derived heparin products.

Synthesis of Anticoagulant Pentasaccharide Fondaparinux via 3,5-Dimethyl-4-(2'-phenylethynylphenyl)phenyl Glycosides

Chemical synthesis and pharmacological properties of heparin pentasaccharide analogues

Catalytic Effects of Different Heparin Analogs on the Hydrolysis of Auramine O.

Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540)

Preparation and structural characterization of a sulfated octasaccharide with heparin-like anticoagulant activity

An Efficient Procedure for Preparing Main Acylated Pentasaccharides from Polygalae Radix Using Integrated Extraction–adsorption Method Followed by Semi-Preparative High Performance Liquid Chromatography

Chemobiocatalytic Synthesis of a Low-Molecular-Weight Heparin

Synthesis and Biological Profiling of Seven Heparin and Heparan Sulphate Analogue Trisaccharides

STUDIES OF NEW-TYPE HEPARINIZED POLYSTYRENE FILM SURFACES AND THEIR ANTITHROMBOGENICITY IN VITRO

Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin

Preparation of Low Molecular Weight Heparin Using an Ultrasound-Assisted Fenton-system

An In Situ Gel-Forming Heparin-Conjugated PLGA-PEG-PLGA Copolymer

E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor

Automated solution-phase multiplicative synthesis of complex glycans up to a 1,080-mer

A heparin derivatives library constructed by chemical modification and enzymatic depolymerization for exploitation of non-anticoagulant functions

Biosynthetic production of anticoagulant heparin polysaccharides through metabolic and sulfotransferases engineering strategies

Structural Characterization and Anticoagulant Activity of a 3-O-Methylated Heteroglycan From Fruiting Bodies of Pleurotus placentodes

Synthesis of Fucosylated Chondroitin Sulfate Nonasaccharide As a Novel Anticoagulant Targeting Intrinsic Factor Xase Complex

Enzymatic access to the rare ΔUA (1→4) Glc 3, 6, N-sulfated heparin disaccharide, implications for heparin quality control

Synthesis of C4‐Acyl‐tetrofuranosides and C5‐Acyl‐pentopyranosides Enabled by the Liebeskind‐Srogl Cross‐Coupling Reaction

Synthesis of Fucosylated Chondroitin Sulfate Glycoclusters: A Robust Route to New Anticoagulant Agents.